Cardinal Health Q2 revenue up 12% to $57.4B; non-GAAP EPS $1.82 (+38%); FY24 guidance raised

CARDINAL HEALTH INC

2024-FY EPS reported $1.50 revenue$112,208,000,000

GAAP diluted EPS $1.43 vs. $(0.50) prior year; non-GAAP operating earnings $562M, up 20%.
Pharmaceutical segment profit $518M (+12%); Medical segment profit $71M vs. $17M.
FY24 non-GAAP EPS guidance raised to $7.20-$7.35 from $6.75-$7.00; adj. free cash flow ~$2.5B.
Announced acquisition of Specialty Networks, a tech-enabled multi-specialty GPO and practice enhancement organization.
Revenue $57.4B, driven by brand/specialty pharmaceutical sales growth and COVID-19 vaccine distribution.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CARDINAL HEALTH INC reported the quarter ended December 31, 2023 results: revenue $57.4 billion, EPS $1.43. Guidance raised.

Period: the quarter ended December 31, 2023
Revenue: $57.4 billion
EPS: $1.43
Guidance: raised
Result: reported results

Exact text from the filing

report. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook • Revenue increased 12% to $57.4 billion • GAAP 1 operating earnings were $482 million; GAAP diluted EPS was $1.43 • Non-GAAP operating earnings increased 20% to $562 million; non-GAAP diluted EPS increased 38% to $1.82

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

CARDINAL HEALTH INC filing history →

Source: SEC EDGAR

accession 0001628280-24-002805

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.